about
Isothiocyanates Are Promising Compounds against Oxidative Stress, Neuroinflammation and Cell Death that May Benefit Neurodegeneration in Parkinson's DiseaseUrinary Levels of IL-1β and GDNF in Preterm Neonates as Potential Biomarkers of Motor Development: A Prospective Study.Mast Cells Release Chemokine CCL2 in Response to Parkinsonian Toxin 1-Methyl-4-Phenyl-Pyridinium (MPP(+))Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress.Parkin clearance of dysfunctional mitochondria regulates ROS levels and increases survival of human chondrocytes.Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.Contribution of Pro-inflammatory Cytokine Signaling within Midbrain Periaqueductal Gray to Pain Sensitivity in Parkinson's Disease via GABAergic Pathway.Spinal cord injury and Parkinson's disease: a population-based, propensity score-matched, longitudinal follow-up study.The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease.Maternal Hypermethioninemia Affects Neurons Number, Neurotrophins Levels, Energy Metabolism, and Na(+),K(+)-ATPase Expression/Content in Brain of Rat Offspring.Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism.Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.An Inflammation-Centric View of Neurological Disease: Beyond the Neuron.Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson's disease.
P2860
Q28079206-498D5E3B-67E8-48C5-A924-5BDC0CFB789FQ33695610-2166B909-329A-4264-AD28-2093F07D8F90Q36805502-6C6C124F-C182-40AB-81E3-B1F0098DDA4DQ38617807-24D72AF4-1DDB-4F21-936C-AC0C3DE12821Q38628365-AFA36951-C5D5-402B-9C2E-D9CC618B9CFFQ38668948-48834952-8088-4CB3-B0BA-46E1EBB63C0DQ39509256-8D70908D-7C79-4017-BEE3-FE98169845D4Q40728161-4CD84467-0501-42AA-B068-0C725070BE93Q41913461-F89A817E-B163-4A06-9C3F-AB328ED1370CQ48358928-3AB75960-9B87-4AF9-9DF0-B488AFE9B0B4Q49797218-21F7C34D-3AA8-45D5-A44B-C9BBD3CE913CQ50235339-CD0CDA2B-361C-4590-8C17-ABFA0836D228Q52331711-C74C008B-FA61-41CC-BAA8-4DC853CB8684Q55360734-BE6D67B8-FA1B-4664-9247-02A365C0B53FQ55517799-812C85BC-9EA0-49F6-8D5B-2BCB190A268E
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 March 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Parkinson's disease and enhanced inflammatory response.
@en
Parkinson's disease and enhanced inflammatory response.
@nl
type
label
Parkinson's disease and enhanced inflammatory response.
@en
Parkinson's disease and enhanced inflammatory response.
@nl
prefLabel
Parkinson's disease and enhanced inflammatory response.
@en
Parkinson's disease and enhanced inflammatory response.
@nl
P2860
P356
P1476
Parkinson's disease and enhanced inflammatory response
@en
P2093
Brad E Morrison
Brandon M Wagner
P2860
P304
P356
10.1177/1535370215576313
P577
2015-03-13T00:00:00Z